{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:54:24Z","timestamp":1793386464514,"version":"4.5.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.clinthera.2010.01.021","type":"journal-article","created":{"date-parts":[[2010,2,3]],"date-time":"2010-02-03T05:26:28Z","timestamp":1265174788000},"page":"S3-S20","source":"Crossref","is-referenced-by-count":88,"special_numbering":"S1","title":["Aripiprazole in schizophrenia and schizoaffective disorder: A review"],"prefix":"10.1016","volume":"32","author":[{"given":"Emmanuel","family":"Stip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Tourjman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2010.01.021_bib1","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLo S Med."},{"key":"10.1016\/j.clinthera.2010.01.021_bib2","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0006-3223(01)01303-8","article-title":"The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches [published correction appears in Biol Psychiatry. 2002;51:346]","volume":"50","author":"Lieberman","year":"2001","journal-title":"Biol Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib3","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1176\/appi.ajp.163.3.418","article-title":"Determinants of real-world functional performance in schizophrenia subjects: Correlations with cognition, functional capacity, and symptoms","volume":"163","author":"Bowie","year":"2006","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib4","series-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR","year":"2000"},{"key":"10.1016\/j.clinthera.2010.01.021_bib5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1192\/bjp.187.3.248","article-title":"Schizophrenia practice guidelines: International survey and comparison","volume":"187","author":"Gaebel","year":"2005","journal-title":"Br J Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib6","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.4088\/JCP.v68n1115","article-title":"The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 Update","volume":"68","author":"Moore","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib7","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","article-title":"New generation antipsychotics versus low-potency conventional antipsychotics: A systematic review and meta-analysis","volume":"361","author":"Leucht","year":"2003","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2010.01.021_bib8","first-page":"137","article-title":"Novel antipsychotics: Issues and controversies. Typicality of atypical antipsychotics","volume":"25","author":"Stip","year":"2000","journal-title":"J Psychiatry Neurosci."},{"key":"10.1016\/j.clinthera.2010.01.021_bib9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1017\/S1461145703003651","article-title":"Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia","volume":"6","author":"Kasper","year":"2003","journal-title":"Int J Neuropsychopharmacol."},{"key":"10.1016\/j.clinthera.2010.01.021_bib10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0013-7006(05)82401-7","article-title":"Current issues on schizoaffective disorder [in French]","volume":"31","author":"Azorin","year":"2005","journal-title":"Encephale."},{"key":"10.1016\/j.clinthera.2010.01.021_bib11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1176\/appi.ajp.163.3.353","article-title":"Targeting schizophrenia research to patient outcomes","volume":"163","author":"Carpenter","year":"2006","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib12","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s11920-003-0043-z","article-title":"Schizoaffective disorder: Clinical aspects, differential diagnosis, and treatment","volume":"5","author":"Marneros","year":"2003","journal-title":"Curr Psychiatry Rep."},{"key":"10.1016\/j.clinthera.2010.01.021_bib13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1176\/appi.ps.53.1.94","article-title":"Pharmacologic treatment of hospitalized patients with schizoaffective disorder","volume":"53","author":"Flynn","year":"2002","journal-title":"Psychiatr Serv."},{"key":"10.1016\/j.clinthera.2010.01.021_bib14","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2146\/ajhp060343","article-title":"ASHP therapeutic position statement on the use of second-generation antipsychotic medications in the treatment of adults with psychotic disorders","volume":"64","author":"Noel","year":"2007","journal-title":"Am J Health Syst Pharm."},{"key":"10.1016\/j.clinthera.2010.01.021_bib15","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1371\/journal.pmed.0030327","article-title":"Metabolic profiling of CSF: Evidence that early intervention may impact on disease progression and outcome in schizophrenia","volume":"3","author":"Holmes","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.clinthera.2010.01.021_bib16","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/schbul\/sbp054","article-title":"Is early intervention in psychosis cost-effective over the long term?","volume":"35","author":"Mihalopoulos","year":"2009","journal-title":"Schizophr Bull."},{"issue":"Suppl 8","key":"10.1016\/j.clinthera.2010.01.021_bib17","first-page":"S254","article-title":"Impact of atypical antipsychotics on outcomes of care in schizophrenia","volume":"11","author":"Joyce","year":"2005","journal-title":"Am J Manag Care."},{"key":"10.1016\/j.clinthera.2010.01.021_bib18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1017\/S1121189X00001329","article-title":"Is early intervention in psychosis effective?","volume":"17","author":"Ricciardi","year":"2008","journal-title":"Epidemiol Psichiatr Soc."},{"key":"10.1016\/j.clinthera.2010.01.021_bib19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0022-3565(25)10600-9","article-title":"7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity","volume":"274","author":"Kikuchi","year":"1995","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.clinthera.2010.01.021_bib20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4088\/PCC.v07n0602","article-title":"Atypicality of atypical antipsychotics","volume":"7","author":"Farah","year":"2005","journal-title":"Prim Care Companion J Clin Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1586\/14737175.4.4.705","article-title":"Pharmacological treatment strategies for schizophrenia","volume":"4","author":"Lindenmayer","year":"2004","journal-title":"Expert Rev Neurother."},{"key":"10.1016\/j.clinthera.2010.01.021_bib22","doi-asserted-by":"crossref","first-page":"841","DOI":"10.4088\/JCP.v62n1101","article-title":"Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, \u201cGoldilocks\u201d actions at dopa-mine receptors","volume":"62","author":"Stahl","year":"2001","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib23","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/schbul\/sbm074","article-title":"Molecular targets for treating cognitive dysfunction in schizophrenia","volume":"33","author":"Gray","year":"2007","journal-title":"Schizophr Bull."},{"key":"10.1016\/j.clinthera.2010.01.021_bib24","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.schres.2007.06.008","article-title":"Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: A randomized, double-blind, placebocontrolled study","volume":"95","author":"Sumiyoshi","year":"2007","journal-title":"Schizophr Res."},{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2010.01.021_bib25","first-page":"40","article-title":"Atypical antipsychotics in bipolar depression: Potential mechanisms of action","volume":"66","author":"Yatham","year":"2005","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib26","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/89040","article-title":"Advances in schizophrenia","volume":"7","author":"Thaker","year":"2001","journal-title":"Nat Med."},{"key":"10.1016\/j.clinthera.2010.01.021_bib27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.clinthera.2010.01.021_bib28","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0893-133X(98)00099-2","article-title":"Interactions of the novel anti-psychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes","volume":"20","author":"Lawler","year":"1999","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.clinthera.2010.01.021_bib29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor","volume":"441","author":"Jordan","year":"2002","journal-title":"Eur J Pharmacol."},{"key":"10.1016\/j.clinthera.2010.01.021_bib30","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1176\/appi.ajp.2007.06091479","article-title":"Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: A triple tracer PET study","volume":"164","author":"Mamo","year":"2007","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2010.01.021_bib32","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0140-6736(09)60721-2","article-title":"Are new drugs for schizophrenia better than old ones?","volume":"373","author":"Anghelescu","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2010.01.021_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-244X-9-13","article-title":"Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: A post-hoc analysis of 5 double-blind, randomized clinical trials","volume":"9","author":"Stauffer","year":"2009","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.clinthera.2010.01.021_bib34","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Kane","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2010.01.021_bib35","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch Gen Psych."},{"key":"10.1016\/j.clinthera.2010.01.021_bib36","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jpsychires.2007.05.002","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole 10, 15 or 20 mg\/day for the treatment of patients with acute exacerbations of schizophrenia","volume":"41","author":"McEvoy","year":"2007","journal-title":"J Psychiatr Res."},{"key":"10.1016\/j.clinthera.2010.01.021_bib37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","article-title":"Aripiprazole in the treatment of schizophrenia: Safety and tolerability in short-term, placebo-controlled trials","volume":"61","author":"Marder","year":"2003","journal-title":"Schizophr Res."},{"key":"10.1016\/j.clinthera.2010.01.021_bib38","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2010.01.021_bib39","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.schres.2008.06.018","article-title":"The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: A pooled analysis of data from the pivotal trials [published correction appears in Schizophr Res. 2009;107:334\u2013335]","volume":"105","author":"Kane","year":"2008","journal-title":"Schizophr Res."},{"key":"10.1016\/j.clinthera.2010.01.021_bib40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.schres.2005.12.857","article-title":"A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)","volume":"84","author":"Tandon","year":"2006","journal-title":"Schizophr Res."},{"key":"10.1016\/j.clinthera.2010.01.021_bib41","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4088\/JCP.v64n0910","article-title":"Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebocontrolled 26-week study","volume":"64","author":"Pigott","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2010.01.021_bib42","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.biopsych.2008.07.033","article-title":"A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia","volume":"65","author":"Fleischhacker","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.clinthera.2010.01.021_bib43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.schres.2007.05.009","article-title":"Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks","volume":"95","author":"Kane","year":"2007","journal-title":"Schizophr Res."},{"key":"10.1016\/j.clinthera.2010.01.021_bib44","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eurpsy.2007.03.002","article-title":"A multicentre, randomized, natu- ralistic, open-label study between aripiprazole and standard of care in the management of communitytreated schizophrenic patients Schizophrenia Trial of Aripiprazole (STAR) study","volume":"22","author":"Kerwin","year":"2007","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.clinthera.2010.01.021_bib45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00213-006-0564-3","article-title":"Effectiveness of longterm aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: A 52-week, open-label comparison with olanzapine","volume":"189","author":"Chrzanowski","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"issue":"Suppl 18","key":"10.1016\/j.clinthera.2010.01.021_bib46","first-page":"47","article-title":"A comparison of weight change during treatment with olanzapine or aripiprazole: Results from a randomized, double-blind study","volume":"65","author":"McQuade","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2010.01.021_bib47","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4088\/JCP.v68n0604","article-title":"The efficacy and safety of arip iprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study","volume":"68","author":"Berman","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2010.01.021_bib48","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1176\/appi.ajp.160.9.1651","article-title":"A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania","volume":"160","author":"Keck","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2010.01.021_bib49","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1192\/bjp.187.3.235","article-title":"Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: Double-blind, randomised, comparative 12-week trial","volume":"187","author":"Vieta","year":"2005","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.clinthera.2010.01.021_bib50","doi-asserted-by":"crossref","first-page":"626","DOI":"10.4088\/JCP.v67n0414","article-title":"A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder","volume":"67","author":"Keck","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2010.01.021_bib51","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/0269881106059693","article-title":"Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: A 3-week placebo-controlled study","volume":"20","author":"Sachs","year":"2006","journal-title":"J Psychopharmacol."},{"key":"10.1016\/j.clinthera.2010.01.021_bib52","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.4088\/JCP.v68n1003","article-title":"Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: A 100-week, doubleblind study versus placebo","volume":"68","author":"Keck","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2010.01.021_bib53","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jad.2008.12.017","article-title":"The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: Results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials","volume":"115","author":"Glick","year":"2009","journal-title":"J Affect Disord."},{"key":"10.1016\/j.clinthera.2010.01.021_bib54","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/YIC.0b013e32816f7779","article-title":"Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, 4-week study","volume":"22","author":"Zimbroff","year":"2007","journal-title":"Int Clin Psychopharmacol."},{"key":"10.1016\/j.clinthera.2010.01.021_bib55","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF03256145","article-title":"Comparative utility of aripiprazole and haloperidol in schizophrenia: Post hoc analysis of two 52-week, randomized, controlled trials","volume":"7","author":"Kane","year":"2009","journal-title":"Appl Health Econ Health Policy."},{"key":"10.1016\/j.clinthera.2010.01.021_bib56","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1176\/ajp.156.9.1358","article-title":"Memory impairment in schizophrenia: A meta-analysis","volume":"156","author":"Aleman","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2010.01.021_bib57","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/schbul\/11.3.397","article-title":"Positive and negative schizophrenic symptoms, attention, and information processing","volume":"11","author":"Cornblatt","year":"1985","journal-title":"Schizophr Bull."},{"key":"10.1016\/j.clinthera.2010.01.021_bib58","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/archpsyc.1987.01800230088014","article-title":"Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test","volume":"44","author":"Goldberg","year":"1987","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2010.01.021_bib59","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1037\/0894-4105.12.3.426","article-title":"Neurocognitive deficit in schizophrenia: A quantitative review of the evidence","volume":"12","author":"Heinrichs","year":"1998","journal-title":"Neuropsychology"},{"key":"10.1016\/j.clinthera.2010.01.021_bib60","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/schbul\/10.2.160","article-title":"Information processing and attentional functioning in the developmental course of schizophrenic disorders","volume":"10","author":"Nuechterlein","year":"1984","journal-title":"Schizophr Bull."},{"key":"10.1016\/j.clinthera.2010.01.021_bib61","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2004.09.007","article-title":"Identification of separable cognitive factors in schizophrenia","volume":"72","author":"Nuechterlein","year":"2004","journal-title":"Schizophr Res."},{"key":"10.1016\/j.clinthera.2010.01.021_bib62","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1001\/archpsyc.1991.01810310036007","article-title":"Neuropsychological function in schizophrenia, Selective impairment in memory and learning","volume":"48","author":"Saykin","year":"1991","journal-title":"Arch Gen Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib63","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.bandc.2005.07.003","article-title":"Cognitive discernible factors between schizophrenia and schizoaffective disorder","volume":"59","author":"Stip","year":"2005","journal-title":"Brain Cogn."},{"key":"10.1016\/j.clinthera.2010.01.021_bib64","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0013-7006(06)76162-0","article-title":"Cognition, schizophrenia and the effect of antipsychotics [in French]","volume":"32","author":"Stip","year":"2006","journal-title":"Encephale."},{"key":"10.1016\/j.clinthera.2010.01.021_bib65","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00213-006-0428-x","article-title":"The neurocognitive effects of aripiprazole: An open-label comparison with olanzapine","volume":"187","author":"Kern","year":"2006","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.clinthera.2010.01.021_bib66","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0165-1781(02)00030-6","article-title":"Indicators of medication compliance in first-episode psychosis","volume":"110","author":"Kampman","year":"2002","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.clinthera.2010.01.021_bib67","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00131746-200101000-00005","article-title":"Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications","volume":"7","author":"Weiden","year":"2001","journal-title":"J Psychiatr Pract."},{"issue":"Suppl 10","key":"10.1016\/j.clinthera.2010.01.021_bib68","first-page":"45","article-title":"Dosing the antipsychotic medication olanzapine","volume":"58","author":"Nemeroff","year":"1997","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib69","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.schres.2004.07.014","article-title":"High-dose quetiapine in treatment refractory schizophrenia","volume":"73","author":"Pierre","year":"2005","journal-title":"Schizophr Res."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2010.01.021_bib70","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4530(02)00112-9","article-title":"Elevated prolactin levels in patients with schizophrenia: Mechanisms and related adverse effects","volume":"28","author":"Halbreich","year":"2003","journal-title":"Psychoneuroendocrinology."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2010.01.021_bib71","first-page":"20","article-title":"Metabolic considerations in the use of antipsychotic medications: A review of recent evidence","volume":"68","author":"Newcomer","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib72","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2010.01.021_bib73","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of secondgeneration antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib74","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4088\/JCP.08m04421","article-title":"A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia","volume":"70","author":"Kane","year":"2009","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib75","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.schres.2008.09.002","article-title":"Changes in non-high-density lipoprotein cholesterol levels and triglyceride\/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine","volume":"106","author":"Newcomer","year":"2008","journal-title":"Schizophr Res."},{"key":"10.1016\/j.clinthera.2010.01.021_bib76","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4088\/JCP.v69n0702","article-title":"A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine","volume":"69","author":"Newcomer","year":"2008","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib77","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.schres.2005.07.034","article-title":"Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from CATIE schizophrenia trial","volume":"80","author":"Miller","year":"2005","journal-title":"Schizophr Res."},{"key":"10.1016\/j.clinthera.2010.01.021_bib78","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.4088\/JCP.v68n1210","article-title":"Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: A post hoc analysis","volume":"68","author":"Miller del","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib79","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s002130000532","article-title":"Increased dopamine receptor D2 binding after long-term treatment with antipsychotics in humans: A clinical PET study","volume":"152","author":"Sylvestri","year":"2000","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.clinthera.2010.01.021_bib80","unstructured":"Peritogiannis V, Tsouli S. Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature [published online ahead of print, April 24, 2009]. J Psychopharmacol."},{"key":"10.1016\/j.clinthera.2010.01.021_bib81","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.pnpbp.2009.01.009","article-title":"Resolution of risperidone-induced tardive dyskinesia with a switch to aripiprazole monotherapy","volume":"33","author":"Caykoylu","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib82","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/0269881108089591","article-title":"A case of aripiprazole and tardive dyskinesia","volume":"23","author":"Abbasian","year":"2009","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.clinthera.2010.01.021_bib83","first-page":"1","article-title":"Tardive dyskinesia in a patient treated with quetiapine","volume":"8","author":"Rizos","year":"2007","journal-title":"World J Biol Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib84","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.4088\/JCP.v66n0810","article-title":"Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-Month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study","volume":"66","author":"Dossenbach","year":"2005","journal-title":"J Clin Psychiatry."},{"issue":"Suppl 16","key":"10.1016\/j.clinthera.2010.01.021_bib85","first-page":"14","article-title":"Relapse and rehospitalization: Comparing oral and depot antipsychotics","volume":"64","author":"Schooler","year":"2003","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib86","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4088\/JCP.v65n0416","article-title":"Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia","volume":"65","author":"Lindenmeyer","year":"2004","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007999709113338","article-title":"Treatment-resistant schizophrenia\u2014the role of clozapine","volume":"14","author":"Meltzer","year":"1997","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.clinthera.2010.01.021_bib88","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1440-1614.2005.01549.x","article-title":"Clozapine-induced stuttering, facial tics, and myoclonic seizures: A case report","volume":"39","author":"Begum","year":"2005","journal-title":"Aust N Z J Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib89","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1176\/appi.ajp.163.2.204","article-title":"Myocarditis during clozapine treatment [published correction appears in Am J Psychiatry. 2006;163:2556]","volume":"163","author":"Merrill","year":"2006","journal-title":"AmJ Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib90","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis, Incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2010.01.021_bib91","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.yic.0000182114.65134.81","article-title":"Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia","volume":"21","author":"Kane","year":"2006","journal-title":"Int Clin Psychopharmacol."},{"key":"10.1016\/j.clinthera.2010.01.021_bib92","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4088\/JCP.v68n0206","article-title":"Aripiprazole for treatmentresistant schizophrenia","volume":"68","author":"Kane","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.clinthera.2010.01.021_bib93","series-title":"Abilify [prescribing information]","year":"2009"},{"key":"10.1016\/j.clinthera.2010.01.021_bib94","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/026988110401800308","article-title":"Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile","volume":"18","author":"Hirose","year":"2004","journal-title":"J Psychopharmacol."},{"key":"10.1016\/j.clinthera.2010.01.021_bib95","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1517\/14656566.3.12.1773","article-title":"Aripiprazole: Profile on efficacy and safety","volume":"3","author":"Goodnick","year":"2002","journal-title":"Expert Opin Pharmacother."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810000226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810000226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T03:37:11Z","timestamp":1739763431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291810000226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":95,"alternative-id":["S0149291810000226"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.01.021","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}